Management of adverse events of EUS-directed transgastric ERCP procedure
Background and Aims: Accessing the pancreatobiliary region in patients with a history of Roux-en-Y gastric bypass (RYGB) can be challenging. Traditionally, techniques such as percutaneous biliary drainage, enteroscopy-assisted ERCP, and laparoscopy-assisted ERCP have been used. However, each techniq...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-06-01
|
| Series: | VideoGIE |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468448120300333 |
| _version_ | 1797754859117608960 |
|---|---|
| author | Yervant Ichkhanian, MD Thomas Runge, MD Manol Jovani, MD Kia Vosoughi, MD Olaya I. Brewer Gutierrez, MD Mouen A. Khashab, MD |
| author_facet | Yervant Ichkhanian, MD Thomas Runge, MD Manol Jovani, MD Kia Vosoughi, MD Olaya I. Brewer Gutierrez, MD Mouen A. Khashab, MD |
| author_sort | Yervant Ichkhanian, MD |
| collection | DOAJ |
| description | Background and Aims: Accessing the pancreatobiliary region in patients with a history of Roux-en-Y gastric bypass (RYGB) can be challenging. Traditionally, techniques such as percutaneous biliary drainage, enteroscopy-assisted ERCP, and laparoscopy-assisted ERCP have been used. However, each technique has its limitations. EUS–directed transgastric ERCP (EDGE) using a lumen-apposing metal stent (LAMS) has emerged as a novel endoscopic technique for ERCP in patients who have undergone RYGB. The aim of this case series was to highlight LAMS-related shortcomings and adverse events during the periprocedural period. Methods: This was a retrospective review of 4 patients with RYGB anatomy who underwent EDGE for the management of pancreaticobiliary disease and experienced LAMS-related adverse events. Techniques for managing and avoiding these events are discussed. Results: Four patients underwent EDGE with both technical and clinical success. Slight LAMS migration with partial mucosal overgrowth was encountered in 1 case and was managed by LAMS removal. A large, bleeding, distal marginal ulcer after the EDGE procedure was encountered in the second case and was managed with proton pump inhibitor and removal of the LAMS, with fistula treatment with argon plasma coagulation used to enhance closure. The third case was complicated by moderate intraprocedural bleeding after LAMS dilation, which was managed by applying balloon tamponade and placing a through-the-scope esophageal stent across the LAMS. Last, preferential food passage to the excluded stomach was noted in the fourth case and resulted in symptomatic distention. The symptomatic distention was managed by another de novo jejunogastrostomy using a LAMS for drainage. Conclusions: Despite its feasibility and acceptable safety profile, the use of LAMSs during EDGE could be associated with several procedure-specific adverse events, which can be avoided or managed endoscopically with no further consequence. |
| first_indexed | 2024-03-12T17:39:32Z |
| format | Article |
| id | doaj.art-433a999d2fc64b3583ee0ec9bda40b95 |
| institution | Directory Open Access Journal |
| issn | 2468-4481 |
| language | English |
| last_indexed | 2024-03-12T17:39:32Z |
| publishDate | 2020-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | VideoGIE |
| spelling | doaj.art-433a999d2fc64b3583ee0ec9bda40b952023-08-04T05:50:13ZengElsevierVideoGIE2468-44812020-06-0156260263Management of adverse events of EUS-directed transgastric ERCP procedureYervant Ichkhanian, MD0Thomas Runge, MD1Manol Jovani, MD2Kia Vosoughi, MD3Olaya I. Brewer Gutierrez, MD4Mouen A. Khashab, MD5Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, MarylandDivision of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, MarylandDivision of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, MarylandDivision of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, MarylandDivision of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, MarylandDivision of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, MarylandBackground and Aims: Accessing the pancreatobiliary region in patients with a history of Roux-en-Y gastric bypass (RYGB) can be challenging. Traditionally, techniques such as percutaneous biliary drainage, enteroscopy-assisted ERCP, and laparoscopy-assisted ERCP have been used. However, each technique has its limitations. EUS–directed transgastric ERCP (EDGE) using a lumen-apposing metal stent (LAMS) has emerged as a novel endoscopic technique for ERCP in patients who have undergone RYGB. The aim of this case series was to highlight LAMS-related shortcomings and adverse events during the periprocedural period. Methods: This was a retrospective review of 4 patients with RYGB anatomy who underwent EDGE for the management of pancreaticobiliary disease and experienced LAMS-related adverse events. Techniques for managing and avoiding these events are discussed. Results: Four patients underwent EDGE with both technical and clinical success. Slight LAMS migration with partial mucosal overgrowth was encountered in 1 case and was managed by LAMS removal. A large, bleeding, distal marginal ulcer after the EDGE procedure was encountered in the second case and was managed with proton pump inhibitor and removal of the LAMS, with fistula treatment with argon plasma coagulation used to enhance closure. The third case was complicated by moderate intraprocedural bleeding after LAMS dilation, which was managed by applying balloon tamponade and placing a through-the-scope esophageal stent across the LAMS. Last, preferential food passage to the excluded stomach was noted in the fourth case and resulted in symptomatic distention. The symptomatic distention was managed by another de novo jejunogastrostomy using a LAMS for drainage. Conclusions: Despite its feasibility and acceptable safety profile, the use of LAMSs during EDGE could be associated with several procedure-specific adverse events, which can be avoided or managed endoscopically with no further consequence.http://www.sciencedirect.com/science/article/pii/S2468448120300333 |
| spellingShingle | Yervant Ichkhanian, MD Thomas Runge, MD Manol Jovani, MD Kia Vosoughi, MD Olaya I. Brewer Gutierrez, MD Mouen A. Khashab, MD Management of adverse events of EUS-directed transgastric ERCP procedure VideoGIE |
| title | Management of adverse events of EUS-directed transgastric ERCP procedure |
| title_full | Management of adverse events of EUS-directed transgastric ERCP procedure |
| title_fullStr | Management of adverse events of EUS-directed transgastric ERCP procedure |
| title_full_unstemmed | Management of adverse events of EUS-directed transgastric ERCP procedure |
| title_short | Management of adverse events of EUS-directed transgastric ERCP procedure |
| title_sort | management of adverse events of eus directed transgastric ercp procedure |
| url | http://www.sciencedirect.com/science/article/pii/S2468448120300333 |
| work_keys_str_mv | AT yervantichkhanianmd managementofadverseeventsofeusdirectedtransgastricercpprocedure AT thomasrungemd managementofadverseeventsofeusdirectedtransgastricercpprocedure AT manoljovanimd managementofadverseeventsofeusdirectedtransgastricercpprocedure AT kiavosoughimd managementofadverseeventsofeusdirectedtransgastricercpprocedure AT olayaibrewergutierrezmd managementofadverseeventsofeusdirectedtransgastricercpprocedure AT mouenakhashabmd managementofadverseeventsofeusdirectedtransgastricercpprocedure |